Therapeutic option | Strength of evidence |
Subcutaneous sumatriptan | Strong recommendation, moderate-quality evidence |
Intravenous prochlorperazine | Strong recommendation, high-quality evidence |
Intravenous chlorpromazine | Weak recommendation, moderate-quality evidence |
Oral NSAIDs | Strong recommendation, low-quality evidence |
Intravenous lignocaine | Low-quality evidence,5 14 |
Intravenous ketamine | Low-quality evidence15 |
Given the lack of substantive evidence of current inpatient therapy, the significant potential side effect profile and health-economic cost both in prolonged hospital admission and representation there is an urgent need for new therapies.
NSAID, Non-steroidal anti-inflammatory drug.